Please assess the completion status of the following clinical trial:

Trial Title: A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent: Signed informed consent form obtained at screening prior to any procedures being performed.~* Gender: Male or non-pregnant and non-lactating female.~* Age: 18 years or older at time of consent.~* Foot condition: Primary unilateral first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.~* Pain Severity: Presence of moderate or severe pain on a categorical pain intensity scale at Baseline~* Pain Confirmation: On the 0-10 numerical pain intensity scale at Baseline.~* Diary Completion: Be willing and able to record safety and efficacy ratings in the Diaries.~* Safe Transportation Home: Patient must have arrangements for transportation home from the research center accompanied by a responsible adult.~Exclusion Criteria:~* Medical condition: Presence of a serious medical condition, intolerance to NSAIDs, or any other medical condition which, in the opinion of the Investigator, makes the patient unsuitable for participation.~* Infection: Acute infection of the surgical site at the time of surgery that could confound post-surgical evaluation.~* Drug Allergy: History of hypersensitivity to an opioid drug (such as hydrocodone), promethazine, acetaminophen, NSAID (such as ibuprofen or aspirin), midazolam, propofol, mepivacaine, ropivacaine or ketorolac.~* Confounding and Contraindicated Drugs: Other than protocol-permitted medications administered pre-operatively or during surgery: use within 14 days before or during the surgical procedure of any systemic corticosteroid or use within 24 hours or during the surgical procedure of any confounding prescription or non-prescription drug or any drug contraindicated with hydrocodone, acetaminophen, or promethazine. \[Note: Antibiotic for endocarditis prophylaxis (except if known to cause nausea) and aspirin (ASA) ≤ 325 mg for cardiovascular prophylaxis are permitted during the study.\] History of consuming more than 2 alcoholic drinks per day every day for the last month or a positive urine test for opiates, benzodiazepines, barbiturates, tetrahydrocannabinol, methamphetamines, cocaine, oxycodone, cotinine at screening or the morning of surgery will exclude the patient from the trial.~* Investigational Drug Use: Use of an investigational drug within the past 30 days.~* Participated in Study: Previous participation in this study.~* Pregnancy, Lactation: Women who are pregnant or lactating.~* Compliance: Inability to swallow capsules whole.~* Participant relationship: Employee at the research center, employee of the Principal Investigator, Sub-Investigators, or sponsor or relative of the Investigator, Sub-Investigators or research staff who is involved in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CL-108 5 mg (Type: EXPERIMENTAL): Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet
- Norco (Type: ACTIVE_COMPARATOR): hydrocodone 5 mg/APAP 325 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 0 mg matching CL-108

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete